Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.

Voukali M, Kastrinelli I, Stragalinou S, Tasiopoulou D, Paraskevopoulou P, Katsilambros N, Kokkinos A, Tentolouris N, Ioannidis I

Journal of diabetes research4 Aug 2014Cited by 19 (Europe PMC)

PMID25165723PMCIDPMC4137738DOI10.1155/2014/304032PepBankPUB-25165723

Download PDF PubMedAsk about this study

Jump to 5 results

Summary

Therapeutic approaches based on the actions of the incretin hormone GLP-1 have been widely established in the management of T2DM. Nevertheless, much less research has been aimed at elucidating the role of GLP-1 in lipid metabolism and in particular postprandial dyslipidemia. Exenatide and liraglutide are two GLP-1 receptor agonists which are currently available as subcutaneously administered treatment for T2DM but their chronic effects on postprandial lipaemia have not been well investigated. The aim of this study is to examine the effect of treatment with either liraglutide or exenatide for two weeks on postprandial lipaemia in obese subjects with T2DM. This study was a single-center, two-armed, randomized, controlled 2-week prospective intervention trial in 20 subjects with T2DM. Patients were randomized to receive either liraglutide or exenatide treatment and underwent a standardized meal tolerance test early in the morning after 10 h fast at baseline (visit 1, beginning of treatment) and after a two-week treatment period (visit 2). Exenatide and liraglutide both appear to be equally effective in lowering postprandial lipaemia after the first administration and after a two-week treatment. The mechanisms which lead to this phenomenon, which seem to be independent of gastric emptying, are yet to be studied.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, liraglutide lowered postprandial lipaemia after the first administration.
In plain wordsIn obese adults with type 2 diabetes, liraglutide lowered blood fat levels after a meal following the first dose.
Peptide
Liraglutide
Outcome
DecreasePostprandial lipaemia after first administration
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Exenatide and liraglutide both appear to be equally effective in lowering postprandial lipaemia after the first administration and after a two-week treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This study was a single-center, two-armed, randomized, controlled 2-week prospective intervention trial in 20 subjects with T2DM.
Show in the study text Report a problemFND-2516572301
02HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, liraglutide lowered postprandial lipaemia after two weeks of treatment.
In plain wordsIn obese adults with type 2 diabetes, liraglutide lowered blood fat levels after a meal following two weeks of treatment.
Peptide
Liraglutide
Outcome
DecreasePostprandial lipaemia after two weeks
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 2 weeksAs given in this study (human).
Source sentences
Summary
Exenatide and liraglutide both appear to be equally effective in lowering postprandial lipaemia after the first administration and after a two-week treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This study was a single-center, two-armed, randomized, controlled 2-week prospective intervention trial in 20 subjects with T2DM.
Show in the study text Report a problemFND-2516572302
03HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, liraglutide and exenatide were equally effective in lowering postprandial lipaemia.
In plain wordsIn obese adults with type 2 diabetes, liraglutide and exenatide lowered blood fat levels after a meal about equally.
Peptide
Liraglutide
Outcome
No significant changePostprandial lipaemia, liraglutide versus exenatide
Study
n = 20
Comparator
Exenatide
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 2 weeksAs given in this study (human).
Source sentences
Summary
Exenatide and liraglutide both appear to be equally effective in lowering postprandial lipaemia after the first administration and after a two-week treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This study was a single-center, two-armed, randomized, controlled 2-week prospective intervention trial in 20 subjects with T2DM.
Show in the study text Report a problemFND-2516572303
04HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, exenatide and liraglutide appeared equally effective in lowering postprandial lipaemia after the first administration and after two weeks of treatment.
In plain wordsIn obese adults with diabetes, both drugs lowered blood fats after meals after the first dose and after two weeks.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePostprandial lipaemia after first administration and after two weeks
Study
n = 20
Comparator
Liraglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Exenatide and liraglutide both appear to be equally effective in lowering postprandial lipaemia after the first administration and after a two-week treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study is to examine the effect of treatment with either liraglutide or exenatide for two weeks on postprandial lipaemia in obese subjects with T2DM.
Summary · context
This study was a single-center, two-armed, randomized, controlled 2-week prospective intervention trial in 20 subjects with T2DM.
Show in the study text Report a problemFND-2516572304
05HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, exenatide and liraglutide appeared equally effective in lowering postprandial lipaemia after two weeks.
In plain wordsIn obese adults with type 2 diabetes, exenatide and liraglutide appeared equally effective in reducing blood fats after two weeks.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePostprandial lipaemia after two weeks
Study
n = 20
Comparator
Liraglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · two weeksAs given in this study (human).
Source sentences
Summary
Exenatide and liraglutide both appear to be equally effective in lowering postprandial lipaemia after the first administration and after a two-week treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study is to examine the effect of treatment with either liraglutide or exenatide for two weeks on postprandial lipaemia in obese subjects with T2DM.
Summary · context
This study was a single-center, two-armed, randomized, controlled 2-week prospective intervention trial in 20 subjects with T2DM.
Show in the study text Report a problemFND-2516572305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.